IDMP — Identification of Medicinal Products

The ISO suite that gives every medicine a globally unambiguous identity.

0/2 done

Theory

A passport system for medicines

IDMP (Identification of Medicinal Products) is a suite of ISO standards that together give every medicinal product a globally unambiguous identity — essential for pharmacovigilance, recalls and cross-border drug safety. The ISO documents themselves are paywalled, and regulators (the EMA, FDA) drive their adoption.

  • The five core standardsISO 11615 (medicinal product information), ISO 11616 (pharmaceutical product information), ISO 11238 (substances — the SMS), ISO 11239 (dose forms, units of presentation, routes of administration), and ISO 11240 (units of measurement, leaning on UCUM).
  • Why a suite — a 'medicine' is many entangled facts: the marketed product, the abstract pharmaceutical product, the active substances, the strength, the dose form, the units. IDMP gives each facet its own standard and identifier, then ties them together.
  • The regulator's registries — the EMA implements IDMP through SPOR: master data for Substances, Products, Organisations and Referentials. These are the authoritative lookups everyone aligns to.
  • How it's carried — IDMP concepts are increasingly exchanged via HL7 FHIR medicinal-product resources (and historically SPL), so IDMP is the model and FHIR is often the transport.

Use Case Example: An adverse-event report in Spain references a medicine by its IDMP identifiers — the same product, substance and strength identifiers a regulator in Germany resolves against SPOR. Because both sides speak IDMP, the safety signal aggregates across borders instead of being lost in national naming differences.

Analogy

IDMP is a passport-and-visa system for medicines. A traveller isn't identified by name alone — you need passport number, nationality, date of birth, photo, each issued and verified by an authority, all cross-referenced. A medicine likewise can't be safely identified by brand name: IDMP pins down the product, the substances, the strength, the dose form and the units — each with its own authoritative identifier — so a recall or adverse event is unambiguous in every country.

One medicine, five standards

Click a node to focus its neighbourhood · drag to pan · scroll to zoom

The IDMP suite and the regulator's master data

Five ISO standards describe a medicine's facets; the EMA's SPOR registries are the authoritative lookups.

Field guide — health/life licensing & vocabulary

Health and life-science licensing field guide

Healthcare standards are where vocabulary rights matter most because real terms can be clinically and commercially sensitive.

StandardWhat is safe to say in demosWhat needs care in production
SNOMED CTgrammar, architecture, placeholder SCTIDs, high-level role of concepts/descriptions/relationshipsreal SCTIDs/terms/definitions/hierarchy often require affiliate/member licence and jurisdiction review
ICDrole as billing/epidemiology classificationedition, country modification, and use rights vary
LOINClab/observation code rolecheck Regenstrief licence/terms and attribution requirements
HL7 FHIRexchange-resource pattern and profilesimplementation guides can be jurisdiction/vendor-specific
IDMPstructure: MPID/PhPID/Substance/PCID and SPOR ideaISO texts are paywalled; regulator implementation data may have its own terms
GO/OBOopen ontology and annotation patternkeep attribution, evidence, version and source; individual OBO ontologies can differ in exact licence

The mental model: SNOMED says what the clinician meant, ICD says how it is classified for reporting/billing, LOINC says which observation was measured, FHIR carries the data, IDMP identifies the medicine, and GO/OBO explains biological function with evidence.

Reflect

IDMP is the standards story under regulatory pressure: safety demands that a medicine mean exactly one thing worldwide, so the model fragments a 'drug' into separately-identified facets. Complexity here isn't academic — it's what makes a global recall possible.

  • Why might 'identify by brand name' be dangerous for pharmacovigilance across countries?
  • Where else would separating an entity into independently-identified facets improve safety or auditing?

Reading in progress · 0 of 2 activities done